Press Release Tryp Therapeutics Submits Investigational New Drug (IND) Application to US FDA for Planned Phase 2a Clinical Trial in Patients with IBS at Massachusetts General Hospital 2 June 20237 March 2024
Press Release Tryp Therapeutics Announces Closing of Oversubscribed Private Placement of SecuredConvertible Debentures for Gross Proceeds of AUD$2,400,000 27 April 202311 March 2024
Press Release Tryp Therapeutics Completes Psychotherapy Training for Planned Phase 2a Clinical Trial at Massachusetts General Hospital 4 April 202311 March 2024
Press Release Tryp Therapeutics Announces Interim Results for Its Phase II Clinical Trial for the Treatment of Binge Eating Disorder With Psilocybin-Assisted Psychotherapy 5 January 202311 March 2024
Press Release Tryp Therapeutics and Massachusetts General Hospital Sign Letter of Intent for Clinical Study Investigating the Use of Psilocybin-Assisted Psychotherapy for the Treatment of Patients Suffering From Irritable Bowel Syndrome (IBS) 3 January 202311 March 2024
Press Release Tryp Therapeutics to Present at Biotech Showcase on Monday, January 9, 2023 21 December 202211 March 2024
Press Release Tryp Therapeutics Announces Fiscal Year 2022 Financial Results and Reports Corporate Highlights 13 December 202211 March 2024
Press Release Tryp Therapeutics to Webcast Live at VirtualInvestorConferences.com on Thursday, December 15 12 December 202211 March 2024
Press Release Tryp Therapeutics Announces Poster Presentations on the Reduction of Chronic Pain in a Rodent Model with Psilocybin and Intravenous Psilocybin Alters Brain Network Dynamics in Rats at the 2022 Society for Neuroscience Conference 10 November 202211 March 2024
